CHANGE IN RATINGS
downgraded at Deutsche Bank to Sell from Hold and price target cut to $8 from $10.
downgraded at Morgan Stanley from Equal-weight to Underweight. Industry traffic is expected to fall 7.5%-9% in the fourth quarter.
upgraded at Barclays to Overweight from Equal-weight. Price target at $42.
upgraded at Barclays to Overweight from Equal-weight. Price target lowered to $50 from $55.
downgraded at Credit Suisse to Underperform. Price target lowered to $21 from $24.
downgraded at Goldman Sachs to Sell from Neutral based on additional downside potential. Price target cut to $30 from $11.
upgraded at Jefferies to a Buy from Hold. Price target increased to $14 from $10.90.
upgraded at Citigroup from Sell to Hold. New Pre smartphone has the ability to be a blockbuster. $6.50 price target.
upgraded at Goldman Sachs to Neutral from Sell following recent underperformance vs. other large-cap pharma. Price target unchanged at $19.
downgraded at Citigroup from Buy to Hold. $29 price target. Estimates also cut.
STOCK COMMENTS / EPS CHANGES
added to Top Picks list at Citigroup. $15 price target. Buy rating.
numbers lowered at Barclays. Shares now seen reaching $49. Estimates also cut. Underweight rating.
price target cut at Credit Suisse to $275 from $350 based on volume declines. Maintained Outperform rating.
numbers lowered at Morgan Stanley. Shares now seen reaching $36. Estimates also cut, to match the company's new lower guidance for the PBM business. Overweight rating.
numbers cut at Barclays. Shares expected to see $51. Estimates also lowered to reflect lower hospital spending. Overweight rating.
estimates cut at Merrill/BofA to reflect tighter 3G chipset inventories. Company remains positioned well. Buy rating and $42 price target.
target lowered at Credit Suisse to $19 from $21. Maintained Outperform rating.
STRATEGY CALLS / MARKET CALLS
Estimates and price targets were cut for
, according to Barclays Capital. Companies seeing weak end-market demand and will likely post weak near-term results.
This article was written by a staff member of TheStreet.com.